US5595886A
(en)
|
1986-01-27 |
1997-01-21 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
US6048729A
(en)
|
1987-05-01 |
2000-04-11 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6544771B1
(en)
*
|
1987-12-11 |
2003-04-08 |
Cell Genesys, Inc. |
Retroviral gene therapy vectors and therapeutic methods based thereon
|
WO1993000103A1
(en)
*
|
1991-06-21 |
1993-01-07 |
The Wistar Institute Of Anatomy And Biology |
Chimeric envelope proteins for viral targeting
|
US5637483A
(en)
*
|
1991-10-04 |
1997-06-10 |
Whitehead Institute For Biomedical Research |
Irradiated tumor cell vaccine engineered to express GM-CSF
|
US5904920A
(en)
*
|
1991-10-04 |
1999-05-18 |
Whitehead Institute For Biomedical Research |
Regulation of systemic immune responses utilizing cytokines and antigens
|
EP1216710B1
(de)
*
|
1991-10-04 |
2006-04-05 |
Whitehead Institute For Biomedical Research |
Regulierung der systemischen Immunantworten mittels Zytokinen und Antigenen
|
PT101031B
(pt)
*
|
1991-11-05 |
2002-07-31 |
Transkaryotic Therapies Inc |
Processo para o fornecimento de proteinas por terapia genetica
|
US6692737B1
(en)
|
1991-11-05 |
2004-02-17 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6054288A
(en)
*
|
1991-11-05 |
2000-04-25 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6063630A
(en)
|
1991-11-05 |
2000-05-16 |
Transkaryotic Therapies, Inc. |
Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
|
WO1994000133A1
(en)
*
|
1992-06-19 |
1994-01-06 |
The General Hospital Corporation |
Use of mullerian inhibiting substance for treating tumors and for modulating class 1 major histocompatibility antigen expression
|
US5911983A
(en)
*
|
1992-06-26 |
1999-06-15 |
University Of Pittsburgh |
Gene therapy for Gaucher disease using retroviral vectors
|
US6531124B1
(en)
|
1992-07-10 |
2003-03-11 |
Transkaryotic Therapies, Inc. |
In vivo production and delivery of insulinotropin for gene therapy
|
US6670178B1
(en)
|
1992-07-10 |
2003-12-30 |
Transkaryotic Therapies, Inc. |
In Vivo production and delivery of insulinotropin for gene therapy
|
GB9222931D0
(en)
*
|
1992-11-02 |
1992-12-16 |
Sandoz Ltd |
Organic compounds
|
US5830461A
(en)
*
|
1992-11-25 |
1998-11-03 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Methods for promoting wound healing and treating transplant-associated vasculopathy
|
US5658565A
(en)
*
|
1994-06-24 |
1997-08-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Inducible nitric oxide synthase gene for treatment of disease
|
EP0701563A4
(de)
*
|
1993-03-08 |
1997-07-02 |
Univ Pittsburgh |
Gen transfer zur behandlung von bindegewebe eines säugetierwirtes
|
EP0702723B1
(de)
*
|
1993-04-21 |
2002-09-04 |
Institut Pasteur |
Biokompatibles implantat zur in vivo expression und sekretion von therapeutischer verbindung
|
FR2704236B1
(fr)
*
|
1993-04-21 |
1995-06-23 |
Pasteur Institut |
Vecteur rétroviral pour la préparation de cellules recombinantes susceptibles d'être implantées in vivo dans un but thérapeutique.
|
US5591625A
(en)
*
|
1993-11-24 |
1997-01-07 |
Case Western Reserve University |
Transduced mesenchymal stem cells
|
AU1513495A
(en)
*
|
1993-12-14 |
1995-07-03 |
University Of Pittsburgh |
Systemic gene treatment of connective tissue diseases
|
DE4411402A1
(de)
*
|
1994-03-31 |
1995-10-05 |
Juergen Schrader |
DNA-Expressionsvektoren zur Verwendung in der gentherapeutischen Behandlung von Gefäßerkrankungen
|
ES2185705T3
(es)
|
1994-05-02 |
2003-05-01 |
Bernd Groner |
Proteina bifuncional, preparacion y uso.
|
US6013517A
(en)
*
|
1994-05-09 |
2000-01-11 |
Chiron Corporation |
Crossless retroviral vectors
|
WO1995030763A2
(en)
*
|
1994-05-09 |
1995-11-16 |
Chiron Viagene, Inc. |
Retroviral vectors having a reduced recombination rate
|
US6150137A
(en)
|
1994-05-27 |
2000-11-21 |
Ariad Pharmaceuticals, Inc. |
Immunosuppressant target proteins
|
WO1996006933A1
(en)
*
|
1994-08-26 |
1996-03-07 |
Sandoz Ltd. |
Gene therapy for transplantation and inflammatory or thrombotic conditions
|
FR2726005B1
(fr)
*
|
1994-10-10 |
1997-01-03 |
Adim |
Lignees immortalisees de cellules endotheliales cerebrales et leurs applications au traitement de differents troubles ou maladies primaires et secondaires neurologiques ou psychiatriques
|
US6818439B1
(en)
|
1994-12-30 |
2004-11-16 |
Chiron Corporation |
Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
|
CA2228378A1
(en)
*
|
1995-07-31 |
1997-02-13 |
Centre De Recherche De L'hopital Sainte-Justine |
Cytidine deaminase cdna as a positive selectable marker for gene transfer, gene therapy and protein synthesis
|
FR2737731B1
(fr)
|
1995-08-07 |
1997-10-10 |
Pasteur Institut |
Sequence de retroelements naturels ou synthetiques ayant pour fonction de permettre l'insertion de sequences nucleotidiques dans une cellule eucaryote
|
WO1997018319A1
(en)
*
|
1995-11-14 |
1997-05-22 |
Somatix Therapy Corporation |
Joint expression of gtp cyclohydrolase and tyrosine hydroxylase
|
US6242187B1
(en)
|
1996-01-29 |
2001-06-05 |
Virologic, Inc. |
Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
|
US5837464A
(en)
*
|
1996-01-29 |
1998-11-17 |
Virologic, Inc. |
Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
|
US6689757B1
(en)
|
1996-02-12 |
2004-02-10 |
M.L. Laboratories Plc |
Methods for vaccination and vaccines therefor
|
AU1873097A
(en)
*
|
1996-02-14 |
1997-09-02 |
New England Deaconess Hospital Corporation |
Gene therapy of entothelial cells with anti-apoptotic proteins for transplantation and inflammatory conditions
|
US5965126A
(en)
*
|
1996-03-25 |
1999-10-12 |
The Penn State Research Foundation |
use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
|
US6723531B2
(en)
|
1996-04-05 |
2004-04-20 |
The Salk Institute For Biological Studies |
Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
AUPN970196A0
(en)
*
|
1996-05-06 |
1996-05-30 |
Unisearch Limited |
A long-term and high expression, single gene retroviral vector with applications to progenitor and mature haematopoietic cells
|
US6027721A
(en)
*
|
1996-05-20 |
2000-02-22 |
Cytotherapeutics, Inc. |
Device and method for encapsulated gene therapy
|
US5885829A
(en)
*
|
1996-05-28 |
1999-03-23 |
The Regents Of The University Of Michigan |
Engineering oral tissues
|
US6001816A
(en)
*
|
1996-06-20 |
1999-12-14 |
Merck & Co., Inc. |
Gene therapy for leptin deficiency
|
CA2258755A1
(en)
*
|
1996-06-20 |
1997-12-24 |
Merck & Co., Inc. |
Gene therapy for obesity
|
AU4401297A
(en)
*
|
1996-09-21 |
1998-04-14 |
Viromedica Pacific Limited |
Improved retroviral vectors for gene therapy
|
US5833651A
(en)
*
|
1996-11-08 |
1998-11-10 |
Medtronic, Inc. |
Therapeutic intraluminal stents
|
US5980887A
(en)
|
1996-11-08 |
1999-11-09 |
St. Elizabeth's Medical Center Of Boston |
Methods for enhancing angiogenesis with endothelial progenitor cells
|
US8075880B2
(en)
|
1999-01-11 |
2011-12-13 |
Steward St. Elizabeth's Medical Center Of Boston, Inc. |
Compositions and methods for regulating angiogenesis
|
WO1998042854A1
(en)
*
|
1997-03-27 |
1998-10-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Functional genomic screen for rna regulatory sequences and interacting molecules
|
US6300488B1
(en)
|
1997-07-10 |
2001-10-09 |
The Salk Institute For Biological Studies |
Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression
|
AU750803B2
(en)
|
1997-10-29 |
2002-07-25 |
University Of Pittsburgh |
Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies
|
CA2305787A1
(en)
|
2000-05-09 |
2001-11-09 |
The University Of British Columbia |
Cxcr4 antagonist treatment of hematopoietic cells
|
CA2245224A1
(en)
|
1998-08-14 |
2000-02-14 |
Jiang-Hong Giong |
Chemokine receptor antagonists and chemotherapeutics
|
US6946445B1
(en)
|
1998-03-13 |
2005-09-20 |
The University Of British Columbia |
Therapeutic chemokine receptor antagonists
|
US6743631B1
(en)
|
1998-03-17 |
2004-06-01 |
North Shore University Hospital Research Corporation |
Use of human serum resistant vector particles and cell lines for human gene therapy
|
US6841537B1
(en)
|
1998-04-22 |
2005-01-11 |
Protiva Biotherapeutics Inc. |
Combination therapy using nucleic acids and conventional drugs
|
US6841538B1
(en)
|
1998-04-22 |
2005-01-11 |
Inex Pharmaceuticals Corporation |
Combination therapy using nucleic acids and radio therapy
|
DE19822115B4
(de)
*
|
1998-05-08 |
2004-04-08 |
Heinrich-Pette-Institut |
Retrovirale Gentransfervektoren
|
US6333318B1
(en)
|
1998-05-14 |
2001-12-25 |
The Salk Institute For Biological Studies |
Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
AU3998799A
(en)
*
|
1998-05-20 |
1999-12-06 |
Genentech Inc. |
Treatment for hemophilia
|
AU773015B2
(en)
*
|
1998-05-26 |
2004-05-13 |
Innova Science Pte. Ltd. |
Lentiviral vectors
|
US6319905B1
(en)
|
1998-12-29 |
2001-11-20 |
Cell Genesys, Inc. |
Method of controlling L-Dopa production and of treating dopamine deficiency
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
AU767066B2
(en)
|
1999-03-03 |
2003-10-30 |
Curis, Inc. |
Methods of modulating lipid metabolism and storage
|
EP1161528A1
(de)
|
1999-03-12 |
2001-12-12 |
GPC Biotech Inc. |
Methoden und reagentien zur identifikation von synthetischen genetischen elementen
|
US7396905B1
(en)
|
1999-05-21 |
2008-07-08 |
Mckeon Frank |
Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
|
US7504253B2
(en)
|
1999-06-11 |
2009-03-17 |
The Burnham Institute For Medical Research |
Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof
|
US7057015B1
(en)
|
1999-10-20 |
2006-06-06 |
The Salk Institute For Biological Studies |
Hormone receptor functional dimers and methods of their use
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
US6951839B1
(en)
|
1999-11-30 |
2005-10-04 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
US8168178B2
(en)
|
1999-11-30 |
2012-05-01 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
GB9930616D0
(en)
|
1999-12-24 |
2000-02-16 |
Mathilda & Terence Kennedy Ins |
Activation and inhibition of the immune system
|
EP1254169B1
(de)
|
1999-12-30 |
2007-05-09 |
President And Fellows of Harvard College |
Verfahren zur modulierung der aktivität von th2-zellen durch modulierung der aktivität von xbp-1
|
US20010053769A1
(en)
|
2000-01-21 |
2001-12-20 |
Christiane Ferran |
Use of pro-apoptotic factors in treatment of atherosclerosis
|
US20050059584A1
(en)
|
2002-08-16 |
2005-03-17 |
Ahmed Merzouk |
Novel chemokine mimetics synthesis and their use
|
US7378098B2
(en)
|
2000-04-12 |
2008-05-27 |
The University Of British Columbia |
CXC chemokine receptor 4 agonist peptides
|
US7368425B2
(en)
|
2006-03-24 |
2008-05-06 |
Chemokine Therapeutics Corp. |
Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
|
WO2001090342A2
(en)
|
2000-05-22 |
2001-11-29 |
Johns Hopkins University |
Genetic engineering of vascular grafts to resist disease
|
CA2432542A1
(en)
|
2000-12-22 |
2002-07-04 |
Synovis Limited |
Methods of modulating toll-related receptor (trr) signaling
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
JP4210737B2
(ja)
|
2001-07-12 |
2009-01-21 |
ユニバーシティー オブ マサチューセッツ |
遺伝子サイレンシングを仲介する低分子干渉リボ核酸のインビボにおける製造方法
|
EP1900815B1
(de)
|
2001-07-12 |
2016-09-07 |
University of Massachusetts |
In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
IL152904A0
(en)
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
CA2421269A1
(en)
|
2002-08-09 |
2004-02-09 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
US7470538B2
(en)
|
2002-12-05 |
2008-12-30 |
Case Western Reserve University |
Cell-based therapies for ischemia
|
EP2561887B8
(de)
|
2003-01-14 |
2016-12-21 |
Dana-Farber Cancer Institute, Inc. |
Sensibilisator für Krebstherapie
|
JP4879742B2
(ja)
|
2003-05-16 |
2012-02-22 |
ユニヴェルシテ ラヴァル |
Cnsクロライドの調節およびその使用
|
AU2004248136B2
(en)
|
2003-06-02 |
2011-09-15 |
University Of Massachusetts |
Methods and compositions for controlling efficacy of RNA silencing
|
DE602004029678D1
(de)
|
2003-06-02 |
2010-12-02 |
Univ Massachusetts |
Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai
|
EP2441474B1
(de)
|
2003-10-17 |
2015-08-05 |
Joslin Diabetes Center, Inc. |
Verfahren und Zusammensetzungen zur Modulation der Adipozytfunktion
|
EP1735009A4
(de)
|
2004-03-12 |
2011-03-30 |
Alnylam Pharmaceuticals Inc |
Irna mittel targeting vegf
|
WO2005107817A2
(en)
*
|
2004-04-30 |
2005-11-17 |
Orbus Medical Technologies, Inc. |
Medical device with coating for capturing genetically-altered cells and methods of using same
|
DK1766077T3
(da)
|
2004-06-21 |
2012-07-16 |
Univ Leland Stanford Junior |
Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
|
WO2006017673A2
(en)
|
2004-08-03 |
2006-02-16 |
Biogen Idec Ma Inc. |
Taj in neuronal function
|
DK2529619T3
(en)
|
2005-02-17 |
2016-01-11 |
Biogen Ma Inc |
Treatment of neurological disorders
|
EP1921136B1
(de)
|
2005-08-16 |
2012-12-12 |
Takara Bio, Inc. |
Nukleinsäure zur behandlung oder vorbeugung einer immunschwächevirusinfektion
|
EP1762609B1
(de)
|
2005-09-13 |
2012-04-04 |
Takara Bio Inc. |
Serumfreies Medium zur Herstellung von retroviralen Vektoren
|
CA2626584A1
(en)
|
2005-11-04 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of nav1.8 gene
|
US20100069461A1
(en)
|
2005-11-09 |
2010-03-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor v leiden mutant gene
|
US20090019557A1
(en)
|
2005-11-12 |
2009-01-15 |
Huda Akil |
Fgf2-related methods for diagnosing and treating depression
|
AP2809A
(en)
|
2005-11-18 |
2013-12-31 |
Glenmark Pharmaceuticals Sa |
Anti-Alpha2 Integrin antibodies and their uses
|
CA2524619A1
(en)
|
2005-11-22 |
2007-05-22 |
Ottawa Health Research Institute |
Novel stem cells, nucleotide sequences and proteins therefrom
|
US8846393B2
(en)
|
2005-11-29 |
2014-09-30 |
Gamida-Cell Ltd. |
Methods of improving stem cell homing and engraftment
|
NZ587704A
(en)
|
2006-03-31 |
2012-04-27 |
Alnylam Pharmaceuticals Inc |
Use of dsRNA for inhibiting expression of Eg5 gene
|
WO2007127919A2
(en)
|
2006-04-28 |
2007-11-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the jc virus
|
PL2194128T3
(pl)
|
2006-05-11 |
2012-12-31 |
Alnylam Pharmaceuticals Inc |
Kompozycje i sposoby inhibicji ekspresji genu PCSK9
|
US7812150B2
(en)
|
2006-05-19 |
2010-10-12 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of Aha and therapeutic uses thereof
|
CA2653451C
(en)
|
2006-05-22 |
2015-12-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of ikk-b gene
|
EP2839843B1
(de)
|
2006-05-25 |
2018-06-20 |
Biogen MA Inc. |
VLA-1-Antagonisten zur Verwendung bei der Behandlung von Schlaganfall
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
WO2008092041A2
(en)
|
2007-01-24 |
2008-07-31 |
Carnegie Mellon University |
Optical biosensors
|
NZ579050A
(en)
|
2007-02-06 |
2012-10-26 |
Tai June Yoo |
Treatment and prevention of neurodegenerative diseases using gene therapy
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
WO2008133137A1
(ja)
|
2007-04-20 |
2008-11-06 |
Takara Bio Inc. |
遺伝子治療のためのベクター
|
CN101688206B
(zh)
|
2007-07-05 |
2013-05-15 |
诺瓦提斯公司 |
用于治疗病毒感染的dsRNA
|
EP2245159A2
(de)
|
2007-12-10 |
2010-11-03 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und verfahren zur hemmung der expression des faktor-vii-gens
|
PL2252317T3
(pl)
|
2008-02-15 |
2014-09-30 |
Univ Tufts |
Leczenie zwyrodnienia plamki żółtej
|
US8877896B2
(en)
|
2008-02-15 |
2014-11-04 |
Tufts University |
Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
|
EP2712926A2
(de)
|
2008-03-05 |
2014-04-02 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Expression des Eg5- und des VEGF-Gens
|
JP2011523357A
(ja)
|
2008-05-06 |
2011-08-11 |
ジョスリン ダイアビーティス センター インコーポレイテッド |
褐色脂肪細胞分化を誘導するための方法および組成物
|
EP3208337A1
(de)
|
2008-09-02 |
2017-08-23 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen zur kombinationshemmung der expression eines mutanten egfr und il-6
|
EP3109321B1
(de)
|
2008-09-25 |
2019-05-01 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der serum-amyloid-a-genexpression
|
KR20160079921A
(ko)
|
2008-10-20 |
2016-07-06 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴의 발현을 억제하기 위한 조성물 및 방법
|
PL2894165T3
(pl)
|
2008-11-10 |
2023-04-17 |
Alexion Pharmaceuticals, Inc. |
Sposoby i kompozycje do leczenia zaburzeń układu dopełniacza
|
EP2373382B1
(de)
|
2008-12-10 |
2017-02-15 |
Alnylam Pharmaceuticals, Inc. |
Auf gnaq zielende dsrna-zusammensetzungen und verfahren zur unterdrückung der expression
|
JP2009148273A
(ja)
*
|
2009-01-21 |
2009-07-09 |
Ichikazu Nakao |
内皮細胞を分化増殖させる方法
|
SG173680A1
(en)
|
2009-02-24 |
2011-09-29 |
Alexion Pharma Inc |
Antibodies containing therapeutic tpo/epo mimetic peptides
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
WO2010105209A1
(en)
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
|
ES2900277T3
(es)
|
2009-03-20 |
2022-03-16 |
Mesoblast Inc |
Producción de células pluripotentes reprogramadas
|
US9149024B2
(en)
|
2009-06-22 |
2015-10-06 |
Massachusetts Eye & Ear Infirmary |
Islet1 (Isl1) and hearing loss
|
EP2471901A4
(de)
|
2009-08-25 |
2013-06-26 |
Takara Bio Inc |
Verfahren zur herstellung einer t-zellen-population unter verwendung von retinsäure
|
EP3561077B1
(de)
|
2009-10-21 |
2022-12-21 |
Les Laboratoires Servier |
Verfahren für zellproliferationsbedingte erkrankungen
|
US9745589B2
(en)
|
2010-01-14 |
2017-08-29 |
Cornell University |
Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
|
US20130281510A1
(en)
|
2010-03-29 |
2013-10-24 |
Kumamoto University |
siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
|
WO2011137395A1
(en)
|
2010-04-30 |
2011-11-03 |
Rother Russell P |
Anti-c5a antibodies and methods for using the antibodies
|
WO2012021891A2
(en)
|
2010-08-13 |
2012-02-16 |
Tufts University |
Compositions, kits and methods for treatment of complement-related disorders
|
KR101362111B1
(ko)
|
2010-10-05 |
2014-02-12 |
다카라 바이오 가부시키가이샤 |
바이러스 벡터의 제조방법
|
WO2012051301A1
(en)
|
2010-10-12 |
2012-04-19 |
President And Fellows Of Harvard College |
Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
|
US8815942B2
(en)
|
2010-10-20 |
2014-08-26 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
|
US9958458B2
(en)
|
2010-12-27 |
2018-05-01 |
Brown University |
Therapeutic and diagnostic methods involving biglycan and utrophin
|
US9956236B2
(en)
|
2011-02-07 |
2018-05-01 |
Cornell University |
Methods for increasing immune responses using agents that directly bind to and activate IRE-1
|
US9068184B2
(en)
|
2011-06-21 |
2015-06-30 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein C (PROC) genes
|
KR102369777B1
(ko)
|
2011-06-21 |
2022-03-03 |
알닐람 파마슈티칼스 인코포레이티드 |
아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
|
AU2012308240A1
(en)
|
2011-09-15 |
2013-05-02 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Immunotherapy and diagnosis of mucormycosis using CotH
|
CN104204192A
(zh)
|
2012-02-13 |
2014-12-10 |
加米达细胞有限公司 |
间充质干细胞调理的基质及其产生和使用方法
|
US9399780B2
(en)
|
2012-03-22 |
2016-07-26 |
Takara Bio Inc. |
Method for producing viral vector
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
US9567569B2
(en)
|
2012-07-23 |
2017-02-14 |
Gamida Cell Ltd. |
Methods of culturing and expanding mesenchymal stem cells
|
US20140120116A1
(en)
|
2012-10-26 |
2014-05-01 |
The Chinese University Of Hong Kong |
Treatment of cancer using smad3 inhibitor
|
US9856474B2
(en)
|
2013-01-16 |
2018-01-02 |
Iowa State University Research Foundation, Inc. |
Deep intronic target for splicing correction on spinal muscular atrophy gene
|
EP2851086A1
(de)
|
2013-09-20 |
2015-03-25 |
Sanofi |
Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
|
WO2014128257A1
(en)
|
2013-02-22 |
2014-08-28 |
Sanofi |
Serpins: methods of therapeutic beta-cell regeneration and function
|
EP2769732A1
(de)
|
2013-02-22 |
2014-08-27 |
Sanofi |
Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
|
RU2661101C2
(ru)
|
2013-03-13 |
2018-07-11 |
Дженевив Биосайнсис, Инк. |
Нерепликативные трансдукторные частицы и основанные на трансдукторных частицах репортерные системы
|
EP3003393A4
(de)
|
2013-06-04 |
2017-01-11 |
The Johns Hopkins University |
Dreiteilige theranostische krebs-nukleinsäurekonstrukte
|
EP3003022B1
(de)
|
2013-06-04 |
2017-11-22 |
Virginia Commonwealth University |
Verwendung eines trunkierten ccn1-promotors für krebsdiagnostik, therapeutika und theranostika
|
EP3004357A4
(de)
|
2013-06-04 |
2017-01-11 |
The Johns Hopkins University |
Peg-prom-vermittelte oberflächenexpression von avidin/streptavidin
|
US9701985B2
(en)
|
2013-06-04 |
2017-07-11 |
Virginia Commonwealth University |
mda-9/syntenin promoter to image and treat metastatic cancer cells
|
EP3004153B1
(de)
|
2013-06-04 |
2019-10-30 |
Virginia Commonwealth University |
Rekombinantes cytokin für eine krebstherapie
|
EP3521431A1
(de)
|
2013-09-25 |
2019-08-07 |
Cornell University |
Verbindungen zur induzierung von antitumorimmunität und verfahren dafür
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
SI3191139T1
(sl)
|
2014-07-24 |
2021-03-31 |
Massachusetts Eye & Ear Infirmary |
Genska terapija RPGR za zdravljenje bolezni retinitis pigmentosa
|
JP6651506B2
(ja)
|
2014-08-28 |
2020-02-19 |
タフツ・ユニバーシティ |
補体関連障害を処置するための組成物、方法およびキット
|
US10632151B2
(en)
|
2015-01-22 |
2020-04-28 |
University Of Massachusetts |
Cancer immunotherapy
|
CN107428818A
(zh)
|
2015-01-29 |
2017-12-01 |
密西根州立大学校董会 |
隐藏多肽及其用途
|
DK3265568T3
(da)
|
2015-03-06 |
2020-08-10 |
Massachusetts Eye & Ear Infirmary |
Genaugmentationsterapier til arvelig retinal degeneration forårsaget af mutationer i prpf31-genet
|
WO2016144917A1
(en)
|
2015-03-10 |
2016-09-15 |
University Of Massachusetts |
Targeting gdf6 and bmp signaling for anti-melanoma therapy
|
EP3736287A1
(de)
|
2015-05-11 |
2020-11-11 |
The Johns Hopkins University |
Autoimmunantikörper zur verwendung in der hemmung des krebszellenwachstums
|
WO2016183585A1
(en)
|
2015-05-14 |
2016-11-17 |
Joslin Diabetes Center, Inc. |
Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration
|
US9920100B2
(en)
|
2015-06-05 |
2018-03-20 |
The Chinese University Of Hong Kong |
Mimotopes of tropomyosin for use in immunotherapy for shellfish and/or arthropod allergy
|
WO2017066712A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
WO2017066796A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
CA3005878A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
US11719704B2
(en)
|
2015-12-30 |
2023-08-08 |
Momenta Pharmaceuticals, Inc. |
Methods related to biologics
|
EP3299460A1
(de)
|
2016-09-26 |
2018-03-28 |
Johann Wolfgang Goethe-Universität Frankfurt am Main |
Neuartige verbindungen und verfahren zur modulation der ubiquitinierung
|
WO2018081817A2
(en)
|
2016-10-31 |
2018-05-03 |
University Of Massachusetts |
Targeting microrna-101-3p in cancer therapy
|
WO2018191599A1
(en)
|
2017-04-14 |
2018-10-18 |
University Of Massachusetts |
Brown fat-selective adipokines
|
CN110832072B
(zh)
|
2017-04-21 |
2023-11-07 |
真基因太科公司 |
用于生产非复制型腺病毒的细胞系以及制备所述细胞系的方法
|
CA3066779A1
(en)
|
2017-06-28 |
2019-01-03 |
Regeneron Pharmaceuticals, Inc. |
Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof
|
GB201710973D0
(en)
|
2017-07-07 |
2017-08-23 |
Avacta Life Sciences Ltd |
Scaffold proteins
|
FI3658184T3
(fi)
|
2017-07-27 |
2023-11-30 |
Alexion Pharma Inc |
Korkean pitoisuuden omaavia anti-c5-vasta-aineformulaatioita
|
US11008602B2
(en)
|
2017-12-20 |
2021-05-18 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles and transduction particle-based reporter systems
|
CA3090997A1
(en)
|
2018-02-12 |
2019-08-15 |
Trustees Of Tufts College |
Cd59 for inhibiting inflammasome activation
|
AU2019276372A1
(en)
|
2018-06-01 |
2020-12-24 |
Evotec International Gmbh |
Combination therapy for treating hepatitis B virus infection
|
JP7404335B2
(ja)
|
2018-07-19 |
2023-12-25 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Bcma特異性を有するキメラ抗原受容体およびその使用
|
EP3870602A1
(de)
|
2018-10-23 |
2021-09-01 |
Regeneron Pharmaceuticals, Inc. |
Ny-eso-1-t-zellrezeptoren und verfahren zur verwendung davon
|
WO2020097261A1
(en)
|
2018-11-06 |
2020-05-14 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
New compositions and methods for treating beta-globinopathies
|
WO2020120649A1
(en)
|
2018-12-13 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule
|
WO2020136154A1
(en)
|
2018-12-27 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
Non-replicative transduction particles and transduction particle-based reporter systems for detection of acinetobacter baumannii
|
US11572595B2
(en)
|
2018-12-31 |
2023-02-07 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
|
IT201900007060A1
(it)
|
2019-05-21 |
2020-11-21 |
St Superiore Di Sanita |
Cellule tumorali ingegnerizzate e loro usi
|
IT201900012540A1
(it)
|
2019-07-22 |
2021-01-22 |
Humanitas Mirasole Spa |
Inibitori di CHI3L1 e loro usi
|
CA3147903A1
(en)
|
2019-07-24 |
2021-01-28 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with mage-a4 specificity and uses thereof
|
JP2022544549A
(ja)
|
2019-08-12 |
2022-10-19 |
ピュリノミア バイオテック, インコーポレイテッド |
Cd39発現細胞のadcc標的化を介してt細胞媒介性免疫応答を促進及び増強するための方法及び組成物
|
EP4021934A4
(de)
|
2019-08-30 |
2024-02-14 |
The Regents of the University of California |
Screening-methoden von genfragment-überexpressionen und ihre verwendungen
|
WO2021067526A1
(en)
|
2019-10-02 |
2021-04-08 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
TW202128775A
(zh)
|
2019-10-16 |
2021-08-01 |
英商阿法克塔生命科學有限公司 |
PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
|
IL293450A
(en)
|
2019-12-03 |
2022-07-01 |
Evotec Int Gmbh |
Interferon-related antigen-binding proteins and uses thereof
|
BR112022010425A2
(pt)
|
2019-12-03 |
2022-08-23 |
Evotec Int Gmbh |
Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b
|
EP4085156B1
(de)
|
2019-12-31 |
2023-10-25 |
F. Hoffmann-La Roche AG |
Quantitatives pcr-screening von induzierbaren prophagen aus bakterienisolaten
|
WO2021138581A1
(en)
|
2020-01-03 |
2021-07-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Tnap locally administered for promoting periodontal health
|
MX2022009137A
(es)
|
2020-01-24 |
2022-10-21 |
Regeneron Pharma |
Antígeno expresado preferentemente en receptores de linfocitos t de melanoma (prame) y sus métodos de uso.
|
AU2021259628A1
(en)
|
2020-04-24 |
2023-01-05 |
Millennium Pharmaceuticals, Inc. |
Anti-CD19 antibodies and uses thereof
|
WO2021226063A1
(en)
|
2020-05-05 |
2021-11-11 |
Regeneron Pharmaceuticals, Inc. |
Car comprising cd28 zeta and cd3 zeta
|
US20230365675A1
(en)
|
2020-09-14 |
2023-11-16 |
Vor Biopharma Inc. |
Single domain antibodies against cd33
|
EP4263605A2
(de)
|
2020-12-18 |
2023-10-25 |
Momenta Pharmaceuticals, Inc. |
Antikörper gegen integrin alpha 11 beta 1
|
EP4320149A1
(de)
|
2021-04-09 |
2024-02-14 |
Takeda Pharmaceutical Company Limited |
Gegen komplementfaktor d gerichtete antikörper und verwendungen davon
|
AR125450A1
(es)
|
2021-04-26 |
2023-07-19 |
Millennium Pharm Inc |
Anticuerpos anti-adgre2 y usos de los mismos
|
US20230111279A1
(en)
|
2021-04-26 |
2023-04-13 |
Millennium Pharmaceuticals, Inc. |
Anti-clec12a antibodies and uses thereof
|
KR20240005854A
(ko)
|
2021-05-04 |
2024-01-12 |
리제너론 파아마슈티컬스, 인크. |
Mage-a4 특이성을 갖는 키메라 항원 수용체 및 이들의 용도
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
IL308337A
(en)
|
2021-05-13 |
2024-01-01 |
Us Health |
Preparations and methods for the treatment of sickle cell disease
|
EP4351732A1
(de)
|
2021-06-09 |
2024-04-17 |
Evotec International GmbH |
Interferon-assoziierte antigenbindende proteine zur verwendung zur behandlung oder prävention von coronavirus-infektionen
|
WO2023057946A1
(en)
|
2021-10-07 |
2023-04-13 |
Avacta Life Sciences Limited |
Serum half-life extended pd-l1 binding polypeptides
|
WO2023057567A1
(en)
|
2021-10-07 |
2023-04-13 |
Avacta Life Sciences Limited |
Pd-l1 binding affimers
|
WO2023064255A2
(en)
|
2021-10-15 |
2023-04-20 |
The Regents Of The University Of California |
Diagnosis and treatment of anti-pf4 induced thrombocytopenia
|
KR20240099161A
(ko)
|
2021-10-20 |
2024-06-28 |
다케다 야쿠힌 고교 가부시키가이샤 |
Bcma를 표적화하는 조성물 및 이의 사용 방법
|
WO2023081167A2
(en)
|
2021-11-02 |
2023-05-11 |
The Regents Of The University Of California |
P-selectin mutants and modulation of integrin-mediated signaling
|
IL312903A
(en)
|
2021-11-19 |
2024-07-01 |
Janssen Biotech Inc |
A method for treating geographic atrophy with a gene therapy vector expressing soluble CD59
|
WO2023146807A1
(en)
|
2022-01-25 |
2023-08-03 |
The Regents Of The University Of California |
Vegf mutants and modulation of integrin-mediated signaling
|
WO2023201238A1
(en)
|
2022-04-11 |
2023-10-19 |
Vor Biopharma Inc. |
Binding agents and methods of use thereof
|
WO2023200897A1
(en)
|
2022-04-13 |
2023-10-19 |
The Regents Of The University Of California |
Use of viral il-6 in cancer therapy
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
WO2024091669A1
(en)
|
2022-10-28 |
2024-05-02 |
Ginkgo Bioworks, Inc. |
Chimeric antigen receptors comprising an intracellular domain pair
|
WO2024126294A1
(en)
|
2022-12-13 |
2024-06-20 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
|
WO2024126293A1
(en)
|
2022-12-13 |
2024-06-20 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
|
WO2024126289A1
(en)
|
2022-12-13 |
2024-06-20 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
|